{"name":"Pari Pharma GmbH","slug":"pari-pharma-gmbh","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikgJBVV95cUxQU3hQNWlSV3NHTUNnN1R1Um1POV91M2FNS1hyaXJIUzNIRTdLVzVZMDRVTDhjVWp0Uy1fX3RnUF9ma0VpcFhYX242ejBKaXBmR0VKcjgwdUdyTWJwSE85UUxwQjAzVHh4RjU4c29UQTZBWTdleUFmcWl5YlhTazhNOTMyNGFFXzYtNC1YeEU2NmhnVklTVUoxcnRFcjI3WDhpZF9RX0RCTnp1aUlhSVQ5RHgzelNWZ0NNQlZobFdoZU8yNWkyOXZjN1AyUGpJVzdHWEdiQTR6ZUJ3NWZXaklQNlRUMFBvQm5CR2lrLUNLTVNiYTVZYXVCb1VSYlo4ajVpYkp4d0xZeW9zQkZfUXpyMlFn?oc=5","date":"2025-12-03","type":"patent","source":"BioSpace","summary":"Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System - BioSpace","headline":"Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprieta","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQR0RjdEZxcmlQUXJLWHZhQkhqS3luWDdUVXI4aGk4NVRIUDdSVERfNzFDYkZuNUhKNFNRT0ZwM1ltV3gwVjhjbHlZSUdFWjB6NXhGVWVZQ3ltTTRGMUEyeVpGOXR4eVR5TlEtY3Z2MERldDdVSUdjYU1lZUVIVGx5ZGpWY1NZSGYwRG80c0swTzYtODEyeVlZUHMwV00weHBoNW5iZkQ4cHM?oc=5","date":"2025-04-11","type":"pipeline","source":"Business Wire","summary":"Savara Announces New Employment Inducement Grant - Business Wire","headline":"Savara Announces New Employment Inducement Grant","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxOSElYQnRIendLaGhFUk1PZkdTN0pRaVMtbGNPT0t3VHBHVy04dVJpN043ZDVKRXVCdEU0TUtuc1Z1X3hJc0pCZjBINldvUDhOSGloQjZCMTJyT2Y1NlUwNjd0d0g4ZlBqa2xSVENjbUhYVjVyYUJhMzNrbEF6MmpWQmdiRmVLMzVfTy1aN1lTcUoyMU5hUEdTNERTXzBiWXhlcjNhSEE0azlpQ1dCS2VWcXd3eGIwcVFJaDJlR0ttZWtJem1ndGhtSkVNUkg2eC1rVW82THJYMWNrWTBRdEJWajdHcTNCSGdxTTA0MHFR?oc=5","date":"2023-11-27","type":"pipeline","source":"respiratory-therapy.com","summary":"ARIKACE Benefits CF Patients with Pseudomonas Lung Infections - respiratory-therapy.com","headline":"ARIKACE Benefits CF Patients with Pseudomonas Lung Infections - respiratory","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOeVFGaUZsblFrZWRfaFRZYnJIUkszM3JFN3EwOHI5UEV3emhFekNVb3dBWldYR0dNRFZCV21XbGgtLXRjX3hQOWEyVXJTX01ib1BWd1B1WWdEVU5ILTE5NWZwVnJkUjhXU2dGbWx2clFWVERwOWt2MVJEWWtDS1lCd29WZGpvbHpSWmoxV1lGQWFxQnlXNDlmNVhJZnZWUVAxanlRY3NWR0xsLWlqRVhETXd0V3dRS2hpLWlRU1lkWS1CQQ?oc=5","date":"2023-11-08","type":"pipeline","source":"respiratory-therapy.com","summary":"Arikayce Added to Standard Therapy Benefitted MAC Lung Patients - respiratory-therapy.com","headline":"Arikayce Added to Standard Therapy Benefitted MAC Lung Patients - respiratory","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxORmxBazROZ2pZcW1jSy1ZWE1pYjRPRnZNYnJGcVV2cEZ5YXRfN2pFRmFadDZxVjl2Z3NJczZMenZCSmN2MXp4eGJRU2d4R2pycWdiRFdxUnNSd3Y5YWI0OGc5dTc0QXhpbThMT3d1VkFSM3I0TFB2bmZuTkNVc2dLSTF5Tmw5OUZnNng1MmdFRnc0WEhhY3NMS3FwM3VBWHlXU082T0hBVWJEdWQ1OUdNN015NnJ0dDA?oc=5","date":"2021-06-22","type":"regulatory","source":"PR Newswire","summary":"Dr. Stefan Seemann is appointed President of PARI Pharma GmbH - PR Newswire","headline":"Dr. Stefan Seemann is appointed President of PARI Pharma GmbH","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgJBVV95cUxOcG5kTDNmUTdiZ25NLXVxVHpRTjNoYXBoanNHVE9OX1FEbUZDbWMwUzZtZVNqVGNVZzB2VGRPWmljMUtBUHVKR2JtTm9lWVNYa3ByNW9nZG8yWHduZlJpbmRkVndZREVPcHpYNXJMcU9zVWwxLWNGYVB6RnhqeU9IUTk2U1Bra0RhcVRpZUpzSjRJUzliZHB5dU9nQ0x6S0o0Qm0xcVozR2dUV3pSaGhJR195bDI1S1JGeEcxV1k4UXRIRWNOeGZTcUM4NXY3dG1xQXlUZjFYM2Q2dEI3RlNUNkQwSGpuUzhITjBHRFBKX3Myd1BYSldDUTJKY0lQZ2xBQnl2Y3YtemtaT3Rvc1Y3UXFjTDVmRy1IRlE?oc=5","date":"2021-03-24","type":"pipeline","source":"BioSpace","summary":"LAMIRA®, an eFlow® Technology nebulizer, expected to launch in Japan as a medical device for exclusive administration of ARIKAYCE® (amikacin liposome inhalation suspension) - BioSpace","headline":"LAMIRA®, an eFlow® Technology nebulizer, expected to launch in Japan as a medical device for exclusive administration of","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2021-03-23","type":"regulatory","source":"Insmed Incorporated Investor Relations","summary":"ARIKAYCE® (amikacin liposome inhalation suspension) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients with NTM Lung Disease Caused by MAC Who Did Not Sufficientl","headline":"ARIKAYCE® (amikacin liposome inhalation suspension) Approved by Japan's Ministry of Health, Labour and Welfare for the T","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxPX1BrMWtNUVlDWW5hLVNXaE1uSGxra1doLTh0Si04QndTRUVLZUhJeVl3djdlNXZTMkQ5ZW9NNm9jMDd3NWhGMkg3aGhLNW10N2p2Q1pCRnVmRkpGaVIzR09XUWFUMHV6c0JRcXlBTTl1Q2lnVDVWY3N3WUVYRTFBWTJYbFVXMjZ4MzlEdQ?oc=5","date":"2018-10-04","type":"regulatory","source":"Drug Delivery Business","summary":"Pari Pharma lands FDA nod for Lamira nebulizer - Drug Delivery Business","headline":"Pari Pharma lands FDA nod for Lamira nebulizer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxOQ0VVWWhVWmRkZzV5ck0wZVVqNVNQRThVanRCcHhEdFdPU3F3UXFrZm84NURtcjYweDRrQlZJQW1RMUNrbGxWOWc2QkliWEhCSHh2TWEtQlp1UWhlSE9nWFl2UVlRUkZtV29pQWtxODdrS1JyVEp6LWlHWERNWlhpT0F4MHJmQ3ljaldBT1BfNy1YaVlycVlTX1pERVhXbTVubHZEenR5eWhiX3liYUhkVkV4ak1uYlU2YS1XQ0FETjZSdDdMQ0IxUXdvdTFQcDNaQWk2bzhINU9KTHZkcENVbDZERDhxWFVYdUp6NXl5aw?oc=5","date":"2018-10-03","type":"regulatory","source":"PR Newswire UK","summary":"PARI Pharma's eFlow® Technology device, LAMIRA™, approved as the only nebulizer system to deliver Insmed's ARIKAYCE® (amikacin liposome inhalation suspension) - PR Newswire UK","headline":"PARI Pharma's eFlow® Technology device, LAMIRA™, approved as the only nebulizer system to deliver Insmed's ARIKAYCE® (am","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE5Sc3N3ajRXOHBzbXpGTGZtTHJibFl1Qm9SRWJTSjdNVXh2cHZOMVlIWkpOaFVkYlhlcFBkbjB0bkJfNXltSUljZHNKNWRWZndUZFRaSnRR?oc=5","date":"2017-12-07","type":"regulatory","source":"Medscape","summary":"FDA Clears First Nebulized LAMA Inhaler for COPD - Medscape","headline":"FDA Clears First Nebulized LAMA Inhaler for COPD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxQVFZGVkxKZW9wS1Bza3Jfdm1mTDBURDF2b2tLSWZiUDU2ZERval9NUWhvcmlfNjkyaVlXeWFJc3Q0dTNoZURFMGFtbWJYWjU5M0J0QUZGYWtuTFJJRVZlbFRKeVo5WkpuY1NpLXVWNEVJWTBhS0FFVzdpei1fd2UyeDY4bjRneFhKdTQ1cFpsVHFLc0hzSXB3d0ZlZzZJX0NlZm5IWDNDcHBHRGQyNXpDWWt5OFc1UHhGdEdtT1hyMnItWU52UFE0Y2x2MW5VSHluamxZV3ZyaTJSZzF2cHBPTWhhbUZpem10dTdYZXRoUnpCQQ?oc=5","date":"2017-12-07","type":"regulatory","source":"PR Newswire UK","summary":"Magnair™ an eFlow® Closed System Nebulizer together with Sunovion's Lonhala™ is the first eFlow technology based product to receive FDA Approval to Treat Chronic Obstructive Pulmonary Disease (COPD) -","headline":"Magnair™ an eFlow® Closed System Nebulizer together with Sunovion's Lonhala™ is the first eFlow technology based product","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxQMFpmUENLSUdTR2JUYV9uOXBXbVdZTzZ1OUZjUXJiVDBueUZNOUtMSnFxM3QyOURzc3hzOVRPVVJPZC04aU13cHZvR1M3NktvNEs3em1JT1lnSkIzOU1FcnItblNSQ29ITlVvYWxlbjRYcVYzY2xYX21BOGRSc2FmdHIyQkYzUlNZOVppZmFITTBaTF93Z2g5Q0pHMi0xNTgyd1RYV2pLWkREY0F2cEVBaTRXVUMwTTNfWXlfOG9zWjNycG9YZHFWT2dpaEhvU3BWd3VCZDhmR0c1Zw?oc=5","date":"2017-03-08","type":"trial","source":"BioSpace","summary":"Breath Therapeutics Holding BV Spins Out of PARI Pharma With $46 Million and a Ready-to-Go Phase III Drug/Device Combo - BioSpace","headline":"Breath Therapeutics Holding BV Spins Out of PARI Pharma With $46 Million and a Ready-to-Go Phase III Drug/Device Combo","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}